{"id":"albinterferon-alfa-2b","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{"Pregnancy":"null","Paediatric use":"null","Renal impairment":"null","Hepatic impairment":"null"},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00724776","NCT00411385","NCT00964665","NCT00489385","NCT00402428","NCT00759200"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2008","type":"neutral","milestone":"Phase 3 Initiated","description":"Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in  — Chronic Hepatitis C"},{"date":"2009","type":"neutral","milestone":"Phase 1 Initiated","description":"Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients — Chronic Hepatitis C"},{"date":"2010","type":"negative","milestone":"Phase 2 Initiated","description":"Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Sub — Chronic Hepatitis B. Trial terminated early."}],"aiSummary":"Albumin Interferon Alfa-2b is an interferon-based therapy used in combination with ribavirin for chronic hepatitis B and C. It offers extended half-life through albumin fusion, allowing less frequent dosing.","brandName":"ALBINTERFERON ALFA-2B","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"","explanation":"Albumin Interferon Alfa-2b is a modified form of interferon that helps the body's immune system fight viral infections like hepatitis B and C. The drug is designed to stay in the body longer than standard interferons by attaching to albumin, a protein that naturally circulates in the blood. This extended presence means patients may need fewer injections while still receiving effective treatment.","oneSentence":"This drug is a long-acting interferon used with ribavirin to treat chronic hepatitis B and C.","technicalDetail":"Albumin Interferon Alfa-2b works by binding to interferon receptors on cell surfaces, activating JAK-STAT signaling pathways that enhance antiviral defenses and modulate immune responses. The albumin fusion increases the drug's half-life by reducing renal clearance and increasing circulation time. This engineered protein specifically targets cells infected with hepatitis B or C viruses, helping to suppress viral replication and reduce liver inflammation."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"ALBINTERFERON ALFA-2B","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00724776","phase":"Phase 1","title":"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Escalating Single Dose of Albinterferon Alfa 2b (Alb-IFN), Recombinant Human Albumin-interferon Alfa Fusi","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":30,"indication":"Chronic Hepatitis C","completionDate":""},{"nctId":"NCT00411385","phase":"Phase 3","title":"Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","isPivotal":true,"enrollment":933,"indication":"Chronic Hepatitis C","completionDate":"2008-10"},{"nctId":"NCT00964665","phase":"Phase 1","title":"A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":141,"indication":"Chronic Hepatitis B","completionDate":""},{"nctId":"NCT00489385","phase":"Phase 1","title":"An Open Label Non-Randomized Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":41,"indication":"HIV Infections, HCV","completionDate":"2011-03-15"},{"nctId":"NCT00402428","phase":"Phase 3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination With Ribavirin Compared With Peginterferon Alfa-2a in Combination With Ribavirin in Interferon Alfa Naive","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","isPivotal":true,"enrollment":1331,"indication":"Chronic Hepatitis C","completionDate":"2009-02"},{"nctId":"NCT00759200","phase":"Phase 2","title":"An Open-label, Randomized, Multicenter, Active-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of Albinterferon Alfa 2b Administered Every 4 Weeks Plus Ribavirin in Interferon Alfa-","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":525,"indication":"Chronic Hepatitis C","completionDate":"2010-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}